Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8.
Crit Care. 2023.
PMID: 36627655
Free PMC article.
Clinical Trial.